ADC Therapeutics Updates LOTIS-7 Trial Results for ZYNLONTA and Glofitamab in Relapsed or Refractory DLBCL

ADC Therapeutics SA (ADCT) has announced updated results from the LOTIS-7 trial evaluating ZYNLONTA plus Glofitamab in relapsed or refractory DLBCL. The trial achieved its primary endpoint of overall response rate, with a 95% ORR observed in the combination arm. The company plans to submit data to regulatory authorities for potential approval.